TScan Therapeutics (TCRX) Accumulated Depreciation & Amortization (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $2.9 million as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 29.27% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 29.27% decrease, with the full-year FY2025 number at $2.9 million, down 29.27% from a year prior.
- Accumulated Depreciation & Amortization was $2.9 million for Q4 2025 at TScan Therapeutics, down from $4.1 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $5.4 million in Q4 2023 to a low of $2.9 million in Q4 2025.
- A 5-year average of $4.2 million and a median of $4.1 million in 2024 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: surged 175.0% in 2021, then fell 29.27% in 2025.
- TScan Therapeutics' Accumulated Depreciation & Amortization stood at $3.3 million in 2021, then surged by 54.55% to $5.1 million in 2022, then increased by 5.88% to $5.4 million in 2023, then decreased by 24.07% to $4.1 million in 2024, then decreased by 29.27% to $2.9 million in 2025.
- Per Business Quant, the three most recent readings for TCRX's Accumulated Depreciation & Amortization are $2.9 million (Q4 2025), $4.1 million (Q4 2024), and $5.4 million (Q4 2023).